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Introduction: Extensive surveys on the prevalence of anti- AAV an-
tibodies in humans have been published indicating that prevalence 
varies dependent on serotype, and that a significant proportion of in-
dividuals develop humoral immunity against various AAV serotypes 
early in life, starting around 2 years of age. Furthermore, the preva-
lence of antibodies to different AAV serotypes has been reported to 
vary according to geographical location. We performed a neutralizing 
antibody seroprevalence study in South African hemophilia B patient 
population (n = 44) using a panel of AAV serotypes suitable for liver 
targeted therapy, to determine the AAV serotypes likely to be of great-
est clinical applicability for the South African hemophilia B population.
Methods: Forty- four hemophilia B patient serum samples were 
obtained from Hemophilia Comprehensive Care Center in 
Johannesburg (South Africa). All the patient serum samples were 
analyzed for the presence of NABs against AAV serotypes 1, 2, 5, 
6 and 8 with the use of highly sensitive luciferase- based bioassays.
Results: The highest prevalence of NABs was found to be against 
the AAV2 serotype, 95% (n = 42/44) followed by the AAV6 sero-
type, 82% (n = 36/44), and the AAV1 serotype 77% (n = 34/44). The 
prevalence of NABs against AAV5 and AAV8 was lower with 66% 
(n = 29/44) for AAV5 and 64% (n = 28/44) for AAV8. Serum samples 
positive for anti- AAV2 NABs had a high occurrence of titers above 
1030 (39%) in comparison to anti- AAV1 NABs (21%), anti- AAV5 
NABs (5%) or anti- AAV8 NABs (7%).The occurrence of samples with 
low titers (ranging from titer of 8 to titer of 50) was the highest for 
anti- AAV8 NABs (32%) and for anti- AAV5 NABs (27%), followed by 
anti- AAV2 (18%) and anti- AAV1 (6%)
Discussion/Conclusion: Currently, an anti- AAV NABs titer of 5 is 
used as an exclusion criteria in most of the systemic AAV- based gene 
therapies. When applying the cut- off of 5, 23% of the analyzed pa-
tients could be treated with AAV1, 5% with AAV2, 34% with AAV5, 
18% with AAV6 and 36% with AAV8- based therapeutics. However, 
we have previously reported that AAV5- neutralizing antibodies do 
not impair the efficacy of in vivo transduction of AAV5- based vector 
up to a measured titer of 340 in humans and 1030 in non- human pri-
mates. Therefore, applying the cut- off of 340 or 1030, either 84% or 
95% of the South African Hemophilia B patients could benefit from 
treatment with AAV5- based gene therapy
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Introduction: Extended half- life (EHL) factor VIII (FVIII) requires im-
provements in half- life (t1/2) & area under the curve (AUC) of 1.3 & 
1.25 times compared to standard half- life (SHL) products. The aim of 
this study is compare pharmacokinetics (PK) after the switch from 
SHL to EHL in patients with hemophilia A (HA).
Methods: Multicenter comparative, cross- sectional, prospective 
study analyzing PK differences after switch from SHL to EHL (ef-
moroctocog alfa [rFVIII- Fc] & rurioctocog alfa pegol [PEG- rFVIII]). 
WAPPS- Hemo® was used to analyze PK parameters with 2- 3 sam-
ples: t1/2; AUC, peak level (PL); trough level at 24, 48 & 72 hours 
(TL24, TL48, TL72); & time to reach FVIII levels of 1, 2, 5% (T1%, 
T2%, T5%). Ratio of t1/2 & AUC, the number of weekly doses & the 
dose/kg/week before & after the switch were compared. Wilcoxon 
& Kruskal- Wallis tests (SPSS®) were used to compare the PK 
parameters.
Results: Eighty- three patients from 8 Spanish hospitals were ana-
lyzed (62 rFVIII- Fc; 21 PEG- rFVIII), 79 had severe HA & 4 moderate 
HA. Median age was 30 years (range = 3- 64) & no differences in 
weight were observed between both periods.
Dose/kg/week & weekly infusion frequency were reduced after the 
switch to EHL, & significant improvements were observed in all PK 
parameters after the change from SHL to EHL (Table 1). The median 
ratios of t1/2 & AUC were 1.3 (IQR:1.2- 1.6) and 1.6 (IQR:1.3- 2.2) in 
the entire cohort. In patients with ≥12 years ratios of t1/2 & AUC 
were 1.4 (IQR:1.3- 1.6) & 1.7 (IQR:1.3- 2.3), and in the cohort of 16 
patients <12 years treated with rFVIII- Fc were 1.3 (IQR:0.9- 1.5) and 
1.4 (IQR:1.1- 2.1).
After the switch to EHL, median weekly dose frequency (30%, 
IQR:0- 33.3%) & dose/kg/week (16.9%, IQR:8.7- 32.8%) were re-
duced. In a small subset of 15 younger patients the dose/kg/week 
was increased a median of 28.6% (IQR:11.7- 40- 7%). No differences 
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were observed in any of the PK parameters & median ratios of t1/2 & 
AUC in patients aged ≥12 years treated with rFVIII- Fc vs. PEG- rFVIII 
(46 rFVIII- Fc; 21 PEG- rFVIII).
Discussion/Conclusion: EHL FVIII have shown significant PK im-
provements in clinical real practice, allowing to reduce weekly infu-
sion number & dose/kg/week. Outside the clinical trial setting, we 
have observed an increase in t1/2 & AUC ratios accordingly to EHL 
definition. Comparisons regarding clinical outcomes (bleeding rate 
after switch) will be performed after a follow- up of 1 year with EHL 
for the full cohort.
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Introduction: Circumcision in the most frequent surgical procedure 
for hemophiliac patients in Muslim and Jewish societies. Social in-
tegrance of hemophilia patient is very important approach that we 
help these patients to be circumcised in safety conditions even hav-
ing a bleeding disorder. We use “Izmir protocol” for circumcision for 
more than 20 years. Fibrin Glue is main stone and two days of fac-
tor substitution are used in hospitalization after general anesthesia. 
However inhibitor positivity is contradictory for Izmir protocol due 
to inefficacy risk with by- passing agents. We generally postpone the 
operation and waiting after eradication of inhibitor with ITI program.
Methods: However for this present case, we planned the elective 
operation while he was using weekly emicizumab prophylaxis for 
2.5 years in the extension program for HAVEN- 2. We prefer to use 
orally tranexamic acid for 7 days and Fibrin Glue application during 
operation as well. Recombinant FVIIa (NovoSeven) application was 
preserved for potential post- op bleedings. aPCC was not already se-
lected according to clinical trial protocol.
Results: Twelve year old boy and severe hemophilia- A (FVIII < 1%) 
and HR inhibitors (12 BU/mL) for last 6 years. Using general anes-
thesia, circumcision operation was completed without bleeding 
only using perioperative Fibrin Glue (Beriplast, Behring) application. 
Tranexamic acid also completed for 7 days perorally. Any by- pass 
agents were used before, during or after the operation.
Discussion/Conclusion: This case report is very important that for 
hoping other Turkish patients with inhibitor who were waiting many 
years for circumcision operation. Ministry of Health was recently ap-
proved and in a cup of months reimbursement will be initiated for 
inhibitor patients. Interestingly circumcision operation for inhibitor 
patients is evaluated as major operation more than minor procedure. 
Emicizumab showed its well known efficacy during and after opera-
tion. And any safety problems were observed.
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Introduction: Issues faced by women with inherited bleeding dis-
orders (WBD) were emphasized in a recent European Hemophilia 
Consortium (EHC) patient survey. The EAHAD WBD Working Group 
aims to gather knowledge and define research priorities on diagnosis 
and management of WBD.
Methods: From 9 May- 3 July'19 an electronic survey on the mul-
tidisciplinary management of heavy menstrual bleeding (HMB) and 
pregnancy was sent to 136 certified European hemophilia treatment 
centers (HTCs), including open questions to identify clinical knowl-
edge gaps and research priorities. Differences in proportions were 
tested with Chi2.
Results: 59 HTCs from 12 Western (WE) and 13 Central/Eastern 
European (CEE) countries completed the survey.
A joint clinic where female patients can consult with a hematologist, 
obstetrician and gynecologist, nurse, psychologist/social worker, 
etc. during one visit exists in 24 HTCs (42%). Reported barriers to 
organize a joint clinic are most often institutional (n = 20), followed 
by physician imposed barriers (such as lack of interest or knowhow, 
n = 14) and financial barriers (n = 10). None of the respondents 
identified lack of interest among patients as a barrier. Most cent-
ers without a joint clinic do have a named obstetrician (81%) and/or 
gynecologist (75%) available for collaboration.
Overall 18/54 (33%) European HTCs do not offer pre- implantation 
genetic diagnosis. Third trimester amniocentesis to guide obstetric 
